Literature DB >> 8597883

Plasma and synovial fluid interleukin-1, interleukin-6 and substance P concentrations in rheumatoid arthritis patients: effect of the nonsteroidal anti inflammatory drugs indomethacin, diclofenac and naproxen.

P Sacerdote1, M Carrabba, A Galante, R Pisati, B Manfredi, A E Panerai.   

Abstract

We performed an open, between patients, placebo controlled study in order to evaluate the effect of the treatment with the non steroidal anti inflammatory drugs indomethacin, diclofenac and naproxen on the concentrations of the cytokines IL-1 beta and IL-6 and of the neuropeptide substance P in plasma and synovial fluid of 24 rheumatoid arthritis patients. All patients had high synovial fluid cytokine and substance P levels, and high plasma cytokine levels at the beginning of the study. The treatment with the non steroidal anti inflammatory drugs significantly decreased both plasma and synovial fluid IL-6 and synovial fluid substance P in comparison to placebo, but did not affect IL-1 beta concentrations. This effect can participate in the therapeutic effect of non steroidal anti inflammatory drugs in rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8597883     DOI: 10.1007/bf01837915

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  28 in total

1.  IL-6/IFN-beta 2 in synovial effusions of patients with rheumatoid arthritis and other arthritides. Identification of several isoforms and studies of cellular sources.

Authors:  N Bhardwaj; U Santhanam; L L Lau; S B Tatter; J Ghrayeb; M Rivelis; R M Steinman; P B Sehgal; L T May
Journal:  J Immunol       Date:  1989-10-01       Impact factor: 5.422

Review 2.  Role of cytokines in experimental arthritis.

Authors:  F M Brennan
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

Review 3.  Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.

Authors:  W P Arend; J M Dayer
Journal:  Arthritis Rheum       Date:  1990-03

4.  Synovial fluid concentration of five different cytokines in rheumatic diseases.

Authors:  C I Westacott; J T Whicher; I C Barnes; D Thompson; A J Swan; P A Dieppe
Journal:  Ann Rheum Dis       Date:  1990-09       Impact factor: 19.103

5.  Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis.

Authors:  A Fontana; H Hengartner; E Weber; K Fehr; P J Grob; G Cohen
Journal:  Rheumatol Int       Date:  1982       Impact factor: 2.631

6.  Effect of ibuprofen and diclofenac on the chemotaxis induced by substance P and transforming growth factor-beta on human monocytes and polymorphonuclear cells.

Authors:  L Locatelli; P Sacerdote; P Mantegazza; A E Panerai
Journal:  Int J Immunopharmacol       Date:  1993-10

7.  Differential effects of indomethacin and dexamethasone on cytokine production in carrageenin-induced rat pleurisy.

Authors:  I Utsunomiya; S Nagai; S Oh-ishi
Journal:  Eur J Pharmacol       Date:  1994-02-03       Impact factor: 4.432

8.  The effect of non-steroidal anti-inflammatory drugs on the accumulation and release of interleukin-1-like activity by peritoneal macrophages from the mouse.

Authors:  A K Bahl; M M Dale; J C Foreman
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

9.  Diclofenac and pirprofen modify pituitary and hypothalamic beta-endorphin concentrations.

Authors:  P Sacerdote; G Monza; P Mantegazza; A E Panerai
Journal:  Pharmacol Res Commun       Date:  1985-08

10.  Inhibition by cyclo-oxygenase inhibitors of interleukin-6 production by human peripheral blood mononuclear cells.

Authors:  H Komatsu; H Yaju; K Chiba; T Okumoto
Journal:  Int J Immunopharmacol       Date:  1991
View more
  14 in total

1.  Investigation into the anti-inflammatory and antigranuloma activity of Colchicum luteum Baker in experimental models.

Authors:  Vinod Nair; Rohit Kumar; Surender Singh; Y K Gupta
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 2.  Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications.

Authors:  R E Kast
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

Review 3.  Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

4.  Development and evaluation of a chromatographic procedure for partial purification of substance P with quantitation by an enzyme immunoassay.

Authors:  W P Fehder; W Z Ho; D E Campbell; W W Tourtellotte; L Michaels; J R Cutilli; M Uvaydova; S D Douglas
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

Review 5.  Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety.

Authors:  Nicholas Moore
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 6.  Clinical pharmacokinetics of naproxen.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

7.  Anti-granuloma activity of Coriandrum sativum in experimental models.

Authors:  Vinod Nair; Surender Singh; Yogendra Kumar Gupta
Journal:  J Ayurveda Integr Med       Date:  2013-01

Review 8.  Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology.

Authors:  Roy Altman; Bill Bosch; Kay Brune; Paola Patrignani; Clarence Young
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

9.  In vivo antiarthritic activity of Rosa centifolia L. flower extract.

Authors:  Rohit Kumar; Vinod Nair; Surender Singh; Yogendra Kumar Gupta
Journal:  Ayu       Date:  2015 Jul-Sep

10.  Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.

Authors:  Richard E Kast; Nicolas Skuli; Georg Karpel-Massler; Guido Frosina; Timothy Ryken; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2017-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.